This review a year ago is the only publication to demonstrate any ATH's interest in macula degeneration. The review has been made by Finkelstein et al. This new animal model could be helpful if they have not started anything else in this respect.

Review

J Neurosci Res

. 2020 Oct;98(10):1889-1904.

doi: 10.1002/jnr.24685. Epub 2020 Jul 9.

Therapeutic applications of chelating drugs in iron metabolic disorders of the brain and retina

Ali Shahandeh ¹, Bang V Bui ¹, David I Finkelstein ², Christine T O Nguyen ¹

Affiliations expand

• PMID: 32643793

DOI: 10.1002/jnr.24685

Abstract

Iron is essential for normal cellular function, however, excessive accumulation of iron in neural tissue has been implicated in both cortical and retinal diseases. The exact role of iron in the pathogenesis of neurodegenerative disorders remains incompletely understood. However, iron-induced damage to the brain and retina is often attributed to the redox ability of iron to generate dangerous free radicals, which exacerbates local oxidative stress and neuronal damage. Iron chelators are compounds designed to scavenge labile iron, aiding to regulate iron bioavailability. Recently there has been growing interest in the application of chelating agents for treatment of diseases including neurodegenerative conditions, characterized by increased oxidative stress. This article reviews both clinical and preclinical evidence relating to the effectiveness of iron chelation therapy in conditions of iron dyshomeostasis linked to neurodegeneration in the brain and retina. The limitations as well as future opportunities iron chelation therapy are discussed.